Patents Examined by Kevin S Orwig
-
Patent number: 11484602Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: GrantFiled: December 14, 2018Date of Patent: November 1, 2022Assignee: BicycleTx LimitedInventors: Liuhong Chen, Philip Huxley, Silvia Pavan, Katerine Van Rietschoten
-
Patent number: 11485756Abstract: A method for preparing a cyclopeptide and a cyclopeptide preparing by the method are disclosed. The method includes the following steps: (A) providing compounds represented by the following formulas (I-1) and (I-2): wherein, G, Ra, Rb, Rc, Rd, and Re are defined in the specification; (B) performing a reaction between the compounds of formulas (I-1) and (I-2) to obtain a compound represented by the following formula (I-3): and (C) performing a cyclization reaction of the compound of formula (I-3) with a catalyst of formula (II) and deprotection to obtain a compound represented by the following formula (III): wherein, G?, Q, M, L1, L2, m, y, and z are defined in the specification.Type: GrantFiled: April 28, 2020Date of Patent: November 1, 2022Assignee: NATIONAL TSING HUA UNIVERSITYInventors: Chien-Tien Chen, Shiue-Shien Weng
-
Patent number: 11471503Abstract: Disclosed is the use of a KOR agonist in combination with a MOR agonist in preparing a drug for treating pain. The KOR agonist is selected from a compound as shown in the general formula (I), and the MOR agonist is selected from a compound as shown in the general formula (II), wherein the definitions of each substituent in the general formula (I) and (II) are the same as defined in the description.Type: GrantFiled: December 5, 2018Date of Patent: October 18, 2022Assignee: Jiangsu Hengrui Medicine Co., Ltd.Inventors: Xiaoxing Huang, Guoqing Cao, Changyong Yang, Lianshan Zhang
-
Patent number: 11458106Abstract: The immunostimulatory effect of lipid nanoparticles (LNPs) continues to block their use for safe and effective delivery of pharmaceutical drugs. Consequently, there exists a need to develop effective LNP delivery systems with an increased therapeutic window that do not trigger an inflammatory response. Disclosed herein are lipid nanoparticles comprising a lipid phase and at least one lipophilic anti-inflammatory agent, and pharmaceutical compositions comprising lipid nanoparticles and methods for using lipid nanoparticles. The anti-inflammatory lipid nanoparticles disclosed herein may further serve as platforms for selective delivery of, for example, nucleic acid segments to target cells and tissues, such as antisense oligonucleotides, DNA, mRNAs, siRNAs, Cas9-guideRNA complex.Type: GrantFiled: May 8, 2017Date of Patent: October 4, 2022Assignee: ASTRAZENECA ABInventors: Lennart Lindfors, Tomas Kjellman
-
Patent number: 11426358Abstract: A transparent or translucent medical active substance patch is provided that includes a matrix of monolayer or multilayer configuration with at least one active substance-containing layer contained therein and a backing layer connected with the matrix. The patch, having been applied to the skin of a first person, has a lightness color value L1 at a place of the skin covered by the patch which is not less than 50% and not more than 200% of a lightness color value L2, with L2 being the lightness value of the region of skin of the same person which surrounds the applied patch, with the same being true of the skin of a second or any other person, provided that for all the persons mentioned, the L2 of their respective skin is in the range from 5° to 100°, especially in the range from 20° to 90°.Type: GrantFiled: March 11, 2020Date of Patent: August 30, 2022Assignee: LTS Lohmann Therapie-Systeme AGInventor: Stefan Bracht
-
Patent number: 11389568Abstract: The present invention relates to a biopolymer-based hydrogel as a functional biomaterial produced by crosslinking in the presence of a photopolymerization initiator. The hydrogel of the present invention is elastic so as to be adapted to various shapes in both in vivo and in vitro applications. It is biocompatible, achieving maximum effects on wound healing as wound dressing and tissue adhesion preventing material. The present invention also relates to a method for producing the biocompatible hydrogel.Type: GrantFiled: April 29, 2019Date of Patent: July 19, 2022Assignee: Science@Home Inc.Inventors: Yoon Sik Lee, Byung Gee Kim, Sung Jun Park, Sang Hyuk Lee
-
Patent number: 11384117Abstract: Novel peptides are described which comprise an amino acid motif selected from the group consisting of “PG”, “GP”, “PI” and “IG” and having up to 10 amino acids upstream and/or downstream of the amino acid motif, wherein “P” in the motif is proline or hydroxyproline and the peptide stimulates the development, maintenance and repair of bone, cartilage and associated connective tissue. The invention further relates to pharmaceutical compositions of these peptides, as well as therapeutic and prophylactic uses of such peptides.Type: GrantFiled: March 28, 2018Date of Patent: July 12, 2022Assignee: Octane Orthobiologics Inc.Inventors: Dennis R. Sindrey, Sydney M. Pugh, Timothy J. N. Smith
-
Patent number: 11369576Abstract: A method for creating a consolidated compound for delivering an immunomodulatory and imiquimod to a patient, comprising diluting immunomodulator extract to a desired dilution by transferring a desired quantity of the concentrated immunomodulator to an associated sterile container, the associated sterile container having a defined volume of diluted immunomodulator after dilution thereof, providing a viscous encapsulation material, selecting a prescribed amount of concentrated immunomodulator, the prescribed amount defined as that amount of the diluted immunomodulator extract required to provide a number of doses equal to the number of dispensable increments from the container containing the viscous encapsulation material, introducing the selected amount of each of the diluted immunomodulator extract into the viscous encapsulation material, introducing an amount of imiquimod into the viscous encapsulation material, and mixing the introduced amount of each of the diluted immunomodulator extracts and the introducType: GrantFiled: January 8, 2018Date of Patent: June 28, 2022Assignee: AVRIO GENETICS LLCInventors: James Strader, Jovan Hutton Pulitzer
-
Patent number: 11357883Abstract: The present disclosure relates to a method for preparing an absorbable haemostatic composition for the body and the haemostatic composition prepared thereby, and the present disclosure is for providing a method for preparing an absorbable haemostatic composition for the body and the haemostatic composition prepared thereby, wherein the haemostatic composition can be used directly on the wound site when bleeding occurs in the surgical area such as surgical operation, trauma, etc. so that hemostasis can be effectively performed, the haemostatic composition can perform wound sealing, tissue repairing promotion, wound surface tissue protection, infection prevention, etc., the haemostatic composition is contained in haemostatic products such as gauze (cotton yarn), sponge, etc. to accelerate the hemostasis speed of the bleeding site and enable rapid hemostasis to be able to shorten the hemostasis time at the same time.Type: GrantFiled: December 6, 2021Date of Patent: June 14, 2022Assignee: MANTIZ LOGITECH CO., LTD.Inventors: Eui Jun Kim, Il Hwan Lee, Hae Jun Jeong, Seong Hwan Kim
-
Patent number: 11352390Abstract: A peptoid compound, a nanometer carrier, a pharmaceutical composition, and use of the pharmaceutical composition in manufacture of a medicament for treatment of a disease related to human epidermal growth factor receptor 1 (EGFR). The peptoid compound includes: cysteine (Cys) subunit, 1,4-butanediamine (Nlys) subunit, piperonylamine subunit, ?-alanine subunit and 1-naphthylamine subunit. The peptoid compound has high affinity and targeting effect to the EGFR protein, and high selectivity, and meanwhile has high medicament loading efficiency, no toxicity, and high safety.Type: GrantFiled: January 3, 2019Date of Patent: June 7, 2022Assignees: BEIJING BOE TECHNOLOGY DEVELOPMENT CO., LTD., BOE TECHNOLOGY GROUP CO., LTD.Inventor: Zijian Zhao
-
Patent number: 11339191Abstract: The present invention relates to peptidomimetic macrocycles comprising at least one macrocycle-forming linker and an amino acid sequence chosen from the group consisting of: i) an amino acid sequence with at least about 50%, 60%, 70%, 80%, 90%, or 95% sequence identity to a human sequence IRAK2 54-71 (SEQ ID No1) and 100% identity with the amino acids in the positions 5-6, 9-11, 14-15 or ii) an amino acid sequence with at least about 50%, 60%, 70, 80%, 90%, or 95% sequence identity to a human sequence IRAKM 66-83 (SEQ ID No2) and 100% identity with the amino acids in the positions 5-6, 9-11, 13-14, wherein the peptidomimetic macrocycle comprises an a-helix and at least two natural or two non-natural amino acids crosslinked by a macrocycle-forming linker. It also concerns method of preparation of said peptidomimetic macrocycles and uses thereof, pharmaceutical composition and uses thereof, in particular as inhibitors of inflammatory pathways.Type: GrantFiled: December 22, 2017Date of Patent: May 24, 2022Assignees: Universite de Montpellier, Centre National de la Recherche Scientifique (CNRS)Inventors: Guillaume Laconde, Muriel Amblard-Caussil, Jean Martinez, Christian Jorgensen, Florence Apparailly-Sechan, Isabelle Duroux-Richard
-
Patent number: 11331367Abstract: Described herein are compounds, formulations, and methods for blocking sporozoite invasion and subsequent liver-stage parasite development of a protozoan parasite, such as Plasmodium falciparum.Type: GrantFiled: December 23, 2019Date of Patent: May 17, 2022Assignee: UNIVERSITY OF SOUTH FLORIDAInventors: Bill J. Baker, Nerida G. Wilson, John H. Adams, Matthew A. Knestrick, Alison Elizabeth Roth
-
Patent number: 11331369Abstract: The present invention provides cyclic depsipeptides of Formula (1), stereoisomers thereof, and veterinary acceptable salts thereof wherein each of R1, R2, R3, R4, L1, and L2, are as defined herein. The present invention also contemplates compositions and methods of treatment as an endoparasiticide with a Formula (1) compound.Type: GrantFiled: November 28, 2018Date of Patent: May 17, 2022Assignee: Zoetis Services LLCInventors: Michael P. Curtis, Susan M. Sheehan, Graham M. Kyne, Matthew W. Bedore, Richard A. Ewin, Paul D. Johnson, Tom L. McTier, Christoper S. Knauer, Rajendran Vairagoundar
-
Patent number: 11325944Abstract: The invention relates to macrocyclic peptides and pharmaceutical compositions thereof. The invention further relates to pharmaceutical compositions for modulating opioid receptor activity.Type: GrantFiled: June 15, 2018Date of Patent: May 10, 2022Assignee: University of Florida Research Foundation, IncorporatedInventors: Jane V. Aldrich, Laura E. Hanold
-
Patent number: 11311599Abstract: The present invention relates to a composition for use in preventing, alleviating, or treating inflammatory disease, or an anti-inflammatory composition, which comprises: ?-1,3-glucan; and the peptide composed of the amino acid sequence of SEQ ID NO: 4. The present invention also relates to an antibacterial composition against bacteria causative of sepsis, which comprises: ?-1,3-glucan; the peptide composed of the amino acid sequence of SEQ ID NO: 4; and an antibiotic. The present invention also relates to a method for preventing or treating an inflammatory disease, the method comprising a step of administering ?-1,3-glucan; and the peptide composed of the amino acid sequence of SEQ ID NO: 4 to a patient.Type: GrantFiled: June 19, 2019Date of Patent: April 26, 2022Assignee: Quegen Biotech Co., Ltd.Inventors: Chul Su Yang, Byeong Hee Park, Je Kyoung Kim, Yong Man Jang, Soo Dong Kim, Min Ji Kim
-
Patent number: 11298310Abstract: A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals.Type: GrantFiled: February 19, 2020Date of Patent: April 12, 2022Assignee: EVOLVED BY NATURE, INC.Inventors: Gregory H. Altman, Rebecca L. Lacouture, Rachel Lee Dow, Rachel M. Lind, Dylan S. Haas
-
Patent number: 11298311Abstract: A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals.Type: GrantFiled: February 20, 2020Date of Patent: April 12, 2022Assignee: EVOLVED BY NATURE, INC.Inventors: Gregory H. Altman, Rebecca L. Lacouture, Rachel Lee Dow, Rachel M. Lind, Dylan S. Haas
-
Patent number: 11298399Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Prader-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.Type: GrantFiled: November 18, 2021Date of Patent: April 12, 2022Assignee: LEVO THERAPEUTICS, INC.Inventors: Christopher Bryant, Mark C. Manning, Ryan E. Holcomb
-
Patent number: 11274126Abstract: The present subject matter provides pH triggered peptides, as well as compositions methods, devices, and systems comprising the same. The pH triggered peptides include cyclic and short linear peptides, and may have higher affinity to a membrane lipid bilayer at low pH than at neutral or high pH.Type: GrantFiled: March 21, 2017Date of Patent: March 15, 2022Assignee: University of Rhode Island Board of TrusteesInventors: Yana K. Reshetnyak, Oleg A. Andreev, Keykavous Parang
-
Patent number: 11266968Abstract: The present invention relates to emulsion-templated silica micro and nano-capsules- and methods for making them. In particular, the template emulsion is stabilized by a biosurfactant that also assists in nucleating the silica shell Mineralizing biosurfactants and stabilized micro- and nano-emulsions useful in forming the emulsion-templated micro- and nano-capsules, and methods for the use of the silica micro- and nano-capsules are also described.Type: GrantFiled: September 16, 2014Date of Patent: March 8, 2022Assignee: The University of QueenslandInventors: Anton Peter Jacob Middelberg, Chun-Xia Zhao, David Wibowo, Brenton Charles Peters